- Home
- ZTEK vs DMAC Comparison
ZTEK vs DMAC Comparison
Compare ZTEK & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZTEK
- DMAC
- Stock Information
- Founded
- ZTEK 2008
- DMAC 2000
- Country
- ZTEK Canada
- DMAC United States
- Employees
- ZTEK N/A
- DMAC N/A
- Industry
- ZTEK Major Chemicals
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- ZTEK Industrials
- DMAC Health Care
- Exchange
- ZTEK Nasdaq
- DMAC Nasdaq
- Market Cap
- ZTEK 165.9M
- DMAC 178.0M
- IPO Year
- ZTEK N/A
- DMAC N/A
- Fundamental
- Price
- ZTEK $1.16
- DMAC $3.76
- Analyst Decision
- ZTEK
- DMAC Strong Buy
- Analyst Count
- ZTEK 0
- DMAC 2
- Target Price
- ZTEK N/A
- DMAC $8.00
- AVG Volume (30 Days)
- ZTEK 33.2K
- DMAC 307.4K
- Earning Date
- ZTEK 08-13-2025
- DMAC 08-06-2025
- Dividend Yield
- ZTEK N/A
- DMAC N/A
- EPS Growth
- ZTEK N/A
- DMAC N/A
- EPS
- ZTEK N/A
- DMAC N/A
- Revenue
- ZTEK $607,016.00
- DMAC N/A
- Revenue This Year
- ZTEK N/A
- DMAC N/A
- Revenue Next Year
- ZTEK N/A
- DMAC N/A
- P/E Ratio
- ZTEK N/A
- DMAC N/A
- Revenue Growth
- ZTEK 2826.26
- DMAC N/A
- 52 Week Low
- ZTEK $0.50
- DMAC $2.80
- 52 Week High
- ZTEK $1.84
- DMAC $6.82
- Technical
- Relative Strength Index (RSI)
- ZTEK 30.38
- DMAC 47.18
- Support Level
- ZTEK $1.03
- DMAC $3.48
- Resistance Level
- ZTEK $1.16
- DMAC $3.99
- Average True Range (ATR)
- ZTEK 0.10
- DMAC 0.32
- MACD
- ZTEK -0.03
- DMAC -0.00
- Stochastic Oscillator
- ZTEK 17.02
- DMAC 41.01
About ZTEK Zentek Ltd.
Zentek Ltd is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection, and treatment. It is focused on commercializing ZENGuard, a patent-pending coating with 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as pharmaceutical products against infectious diseases.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.